ArticleERJ open research2025
Impact of oxygenation strategies on outcome in acute exacerbation of interstitial lung disease.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oxygenation in acute exacerbation of interstitial lung disease:a nationwide survey.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: The benefit of noninvasive ventilation (NIV) in hypoxaemic acute respiratory failure is controversial and has never been studied in acute exacerbation of interstitial lung disease (AE-ILD). The potential protective effects of high-flow nasal cannula oxygen therapy (HFNC) also deserve to be evaluated in AE-ILD. Methods: We aimed to describe the respiratory management and compare outcome of adult patients with AE-ILD according to the initial oxygenation strategies, Results: A multicentre retrospective study has been conducted in intensive care units of four French tertiary hospitals between 1 January 2010 and 31 December 2021 with in-hospital mortality as primary outcome. Among 3962 screened patients, 163 were included: 118 with HFNC and 45 with NIV±HFNC. Analysis of changes in oxygenation strategy applied over the past decade have shown an increase in the use of HFNC, from 33.3% in 2010 to 79.2% in 2020. The adjusted in-hospital mortality rate was 55.2% (95% CI 36.0-74.4%) in the NIV±HFNC group Conclusion: The management of AE-ILD has progressively include the HFNC use during the past decade, despite the lack of evidence in the literature. Our study did not find any superiority of HFNC compared with NIV±HFNC in AE-ILD outcome but deserve further prospective trials with a larger population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.